Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

F. Liu, Joyce; F. Brady, Mark; A. Matulonis, Ursula; Miller, Austin; C. Kohn, Elise; M. Swisher, Elizabeth; Cella, David; P. Tew, William; G. Cloven, Noelle; Y. Muller, Carolyn; P. Bender, David; G. Moore, Richard; P. Michelin, David; E. Waggoner, Steven; A. Geller, Melissa; Fujiwara, Keiichi; D. D'Andre, Stacy; Carney, Michael; Alvarez Secord, Angeles; M. Moxley, Katherine; A. Bookman, Michael

doi:10.1200/jco.21.02011

Public

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial

Published in Journal of Clinical Oncology • Mar 15, 2022

Authors:

Joyce F. Liu

Mark F. Brady

Ursula A. Matulonis

Abstract

PURPOSE Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications from repeated platinum therapy occur. We assessed the activity of two all-oral nonplatinum alternatives, olaparib or olaparib/cediranib, versus platinum-based chemotherapy. PATIENTS A...

Subject

Olaparib

Medicine

Ovarian cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!